Drug Transporters
Drug Transporters
We implement in vitro drug transporter studies to investigate the role of transporters in the pharmacokinetics of drug candidates.
As part of our comprehensive portfolio of ADME-Tox research services we offer the following drug transporter studies:
Transporter Substrate Studies:
In vitro drug transporter substrate studies determine if an investigational drug is a substrate of a transporter.
Transporter Inhibition Studies
In vitro transporter inhibition studies determine if an investigational drug is an inhibitor of a transporter.
Single-Transporter Assays
In vitro single-transporter assays predict the role of transporter in pharmacokinetics an investigational drug.
Multi-Transporter Models
In vitro multi-transporter models investigate transporter interaction effects.
OPTI Panel Assays
OPTI Panel Assays bundle transporter assays to investigate ADME properties, safety, drug-drug interaction (DDI) liabilities, and efficacy.
Custom Transporter Assay Development
Develop novel custom transporter assays based on customer requests.
Extensive portfolio of transporter assays
Our portfolio includes over 100 validated single-transporter assays and multi-transporter models to investigate liver, kidney, intestine, and blood-brain barrier transporters known to be involved in pharmacokinetics, including the transporters typically requested by regulatory agencies.
Transporter Studies as Part of the ADME Strategy
Transporters have become increasingly important in drug development due to the major role they play in absorption, distribution and excretion (ADME) of endogenous and exogenous compounds. Additionally, potential for transporter-mediated drug-drug interactions (DDI) is associated with potential toxicological and pharmacological consequences. Data from transporter studies is used to inform lead selection and optimization decisions.
DDI Transporters for Regulatory Submission
Transporters expressed throughout the body affect the plasma and tissue concentrations of a variety of drugs. In particular, uptake and efflux transporters expressed in the intestine, liver, and kidney have been implicated in a variety of serious DDIs. The US FDA, European Medicines Agency (EMA), International Council for Harmonization (ICH), and Japanese Pharmaceuticals and Medical Devices Agency (PMDA) request in vitro studies be conducted on the transporters listed below for DDI assessment and drug labeling. Each agency has published DDI guidance documents that differ slightly in recommended transporters to be tested, in vitro study design and data interpretation.